Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599697 | 0.82 | MAPK1 (0.45) | LMNANPC1SMN1; SMN2KMT2ACYP19A1 | |
| SCHEMBL6792645 | 0.80 | CCNA2 (0.54) | SMN1; SMN2CYP19A1MAPK1ALDH1A1POLB | |
| SCHEMBL3603809 | 0.79 | ALDH1A1 (0.46) | LMNASMN1; SMN2CYP19A1MAPK1TSHR | |
| SCHEMBL6792450 | 0.74 | CCNA2 (0.50) | CYP19A1ALDH1A1KDM4E | |
| SCHEMBL6634331 | 0.73 | CCNA2 (0.49) | CYP19A1ALDH1A1KDM4E | |
| SCHEMBL3599716 | 0.73 | CCNA2 (0.60) | KMT2AALDH1A1 | |
| SCHEMBL21332805 | 0.72 | SMN1; SMN2 (0.77) | LMNANPC1SMN1; SMN2KMT2ACYP19A1 | |
| SCHEMBL3491679 | 0.72 | ALDH1A1 (0.65) | LMNANPC1SMN1; SMN2KMT2ACYP19A1 | |
| SCHEMBL15920987 | 0.71 | SMN1; SMN2 (0.61) | LMNANPC1SMN1; SMN2KMT2ACYP19A1 | |
| SCHEMBL13495282 | 0.71 | SMN1; SMN2 (0.61) | LMNANPC1SMN1; SMN2KMT2ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118102-B1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| US-8207180-B2 | Tricyclic indoles and (4,5-dihydro) indoles | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-26 | — | — | US | disclosed |
| US-7704994-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-03-25 | — | — | US | disclosed |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK J | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | CDC7, CDK7, CDK17 | LMNA 3538/4885NPC1 1688/4885SMN1; SMN2 4121/4885 |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, TPH1, GRIN2B | LMNA 711/4885NPC1 345/4885SMN1; SMN2 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.